Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arovella Therapeutics Ltd

ALA.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▲ +2.13%

Market Cap $40.34M · Vol 109.37K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$40.34M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

17.65

Momentum

Beta

0.96

vs Market

52W High

$0.07

52.83% below

52W Low

$0.03

4.95% above

Volume

109.37K

Avg 762.90K

P/B

5.30

Price-to-book

ROE

N/A

Return on equity

Free Float

76.52%

Public shares

Shariah Compliance8 STANDARDS

✗ Arovella Therapeutics Ltd (ALA.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALA.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.04%

-21.31%

-30.43%

YTD

-48.39%

-52.00%

-32.81%

+4.35%

Financials & Valuation

TTM · Annual

Total Revenue	$553.54K
Net Income	$-4,785,477.00
Revenue Growth (YoY)	+166.07%
Gross Margin	100.00%
Operating Margin	-1,301.77%
Net Profit Margin	-864.52%
ROE	N/A
ROA · ROIC	-37.78% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	93.09
P/B	5.30
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.21B

Technical Indicators

50-Day SMA	$0.04
200-Day SMA	$0.05
RSI (14)	17.65
Beta	0.96
52-Week High	$0.07
52-Week Low	$0.03

Volume Today	109.37K
Avg Daily Volume (30D)	762.90K
Relative Volume	0.14x
Volatility (10D)	54.75
Volatility (30D)	41.51
Free Float	76.52%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.03 52W High$0.07

Current

Target

$0.03 $0.07

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SJX1S6

ISINAU0000182784

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.14% ARGX.BR argenx SE -0.37% ARGX argenx SE -0.69% 2269.HK WuXi Biologics (Cayman) Inc. +1.56% INSM Insmed Incorporated -6.56%

Company Profile

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. It is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. It focuses on integrating IL-12-TM technology into its solid tumor programs.